HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sunscreen monograph

This article was originally published in The Rose Sheet

Executive Summary

FDA should "move up" anticipated implementation date so standards take effect before 2005, American Academy of Dermatology Association says in April 1 comments. "Proceedings of the UVA consensus conference, summarized in the AADA policy, represent a body of immediately accessible knowledge that should be tapped" and should "substantially shorten the amount of time needed" for FDA to draft a sunscreen monograph amendment, group says. Agency, which postponed Dec. 31, 2002 implementation date to create a comprehensive amendment addressing UVA protection, does not expect a new effective date prior to January 2005 (1"The Rose Sheet" Jan. 7, 2002, p. 3). AADA, Skin Cancer Foundation also urge FDA to remove monograph's SPF "30-plus" cap on labeling...

You may also be interested in...



Sunscreen Monograph Effective Date Extended To Address UVA Standards

The Dec. 31, 2002 implementation date of the OTC sunscreen final monograph has been postponed until further notice for the majority of sunscreens, the agency announces in a 11Dec. 31 Federal Register notice

Stockwatch: Earnings Season Catches An Early Cold As Coronavirus Sweeps In

As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.

 

 

Pipeline Watch: Phase III Readouts For Surufatinib, Tislelizumab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

UsernamePublicRestriction

Register

RS010190

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel